UMIN ID: C000000002
Registered date:01/08/2005
Phase I/IIa trial of autologous tumor vaccination in patients with primary glioblastoma
Basic Information
| Recruitment status | Complete: follow-up complete |
|---|---|
| Health condition(s) or Problem(s) studied | Glioblastoma |
| Date of first enrollment | 2005/07/01 |
| Target sample size | 25 |
| Countries of recruitment | Japan |
| Study type | Interventional |
| Intervention(s) | autologous tumor vaccination |
Outcome(s)
| Primary Outcome | Overall survival |
|---|---|
| Secondary Outcome | Cause-specific survival Progression-free survival |
Key inclusion & exclusion criteria
| Age minimum | 16years-old |
|---|---|
| Age maximum | 75years-old |
| Gender | Male and Female |
| Include criteria | |
| Exclude criteria | 1) Patients have taken or take corticosteroid or anticancer drug. 2) Patients with high intracranical pressure. 3) Patients with severe myelosupression. 4) Patients with malignant tumor or cancer. 5) Pregnant woman. |
Related Information
| Primary Sponsor | Tokyo Womens Medical University |
|---|---|
| Secondary Sponsor | Tsukuba University |
| Source(s) of Monetary Support | Cell Medicine Cooperation |
| Secondary ID(s) |
Contact
| public contact | |
| Name | |
| Address | Japan |
| Telephone | 03-3353-8111 |
| Affiliation | Tokyo Women's Medical University Department of Neurosurgery, Neurological Institute |
| scientific contact | |
| Name | Tomokatsu Hori |
| Address | 8-1 Kawada-cho Sinjuku-ku Tokyo Japan |
| Telephone | 03-3353-8111 |
| Affiliation | Tokyo Women's Medical University Department of Neurosurgery, Neurological Institute |